Abstract
Vitamin D is now widely recognized to have multiple extraskeletal health functions. The liver is one of the major organs involved in its metabolism. Recent studies have demonstrated a very high prevalence of vitamin D deficiency and insufficiency in patients with chronic liver disease and cirrhosis. There is an emerging interest to explore the relationship between vitamin D deficiency and prevalence and severity of non-alcoholic liver disease and response to antiviral therapy in hepatitis C. In this review, we discuss the current status of our understanding of vitamin D metabolism and vitamin D deficiency in patients with chronic liver disease and cirrhosis.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Mora JR, Iwata M, von Andrian UH. Vitamin effects on the immune system: vitamins A and D take centre stage. Nat Rev Immunol. 2008;8(9):685–98.
Cantorna MT, Mahon BD. Mounting evidence for vitamin D as an environmental factor affecting autoimmune disease prevalence. Exp Biol Med (Maywood). 2004;229(11):1136–42.
Nagpal S, Na S, Rathnachalam R. Noncalcemic actions of vitamin D receptor ligands. Endocr Rev. 2005;26(5):662–87.
Timms PM, Mannan N, Hitman GA, et al. Circulating MMP9, vitamin D and variation in the TIMP-1 response with VDR genotype: mechanisms for inflammatory damage in chronic disorders? QJM. 2002;95(12):787–96.
Wortsman J, Matsuoka LY, Chen TC, et al. Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr. 2000;72(3):690–3.
Blum M, Dallal GE, Dawson-Hughes B. Body size and serum 25 hydroxy vitamin D response to oral supplements in healthy older adults. J Am Coll Nutr. 2008;27(2):274–9.
Weisman Y, Harell A, Edelstein S, et al. 1 alpha, 25-Dihydroxyvitamin D3 and 24,25-dihydroxyvitamin D3 in vitro synthesis by human decidua and placenta. Nature. 1979;281(5729):317–9.
Gray TK, Lester GE, Lorenc RS. Evidence for extra-renal 1 alpha-hydroxylation of 25-hydroxyvitamin D3 in pregnancy. Science. 1979;204(4399):1311–3.
Stoffels K, Overbergh L, Bouillon R, et al. Immune regulation of 1alpha-hydroxylase in murine peritoneal macrophages: unravelling the IFNgamma pathway. J Steroid Biochem Mol Biol. 2007;103(3–5):567–71.
Holick MF. Vitamin D: a millenium perspective. J Cell Biochem. 2003;88(2):296–307.
Holick MF, Chen TC. Vitamin D deficiency: a worldwide problem with health consequences. Am J Clin Nutr. 2008;87(4):1080S–6S.
WHO. WHO scientific group on the prevention and management of osteoporosis. Prevention and management of osteoporosis: report of a WHO scientific group. Geneva: World Health Organization; 2003.
• Rosen CJ: Clinical practice. Vitamin D insufficiency. N Engl J Med 2011, 364(3):248–54. A state-of the art review of the topic by an expert in the field. This details current understanding of vitamin D metabolism, its role in various extra-bone conditions and mechanisms, and replacement recommendation.
• IOM (Institute of Medicine) Dietary reference intakes for calcium and vitamin D.Washington, DC: Institute of Medicine, 2011 (http://www.iom.edu/vitaminD.). A long awaited report from the IOM. It updated the defintions of vitamin D deficiency and insufficiency impacting the prevalence and replacement recommendations.
Heaney RP. The vitamin D requirement in health and disease. J Steroid Biochem Mol Biol. 2005;97(1–2):13–9.
Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357(3):266–81.
Holick MF. High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc. 2006;81(3):353–73.
Steingrimsdottir L, Gunnarsson O, Indridason OS, et al. Relationship between serum parathyroid hormone levels, vitamin D sufficiency, and calcium intake. JAMA. 2005;294(18):2336–41.
•• Fisher L, Fisher A: Vitamin D and parathyroid hormone in outpatients with noncholestatic chronic liver disease. Clin Gastroenterol Hepatol 2007, 5(4):513–20. This is the most comprehensive study done to date to examine the prevalence and predictors of vitamin D insufficiency and deficiency in patients with chronic liver disease.
• Arteh J, Narra S, Nair S: Prevalence of vitamin D deficiency in chronic liver disease. Dig Dis Sci 2010, 55(9):2624–8. This prospective study examined the prevalence and predictors of vitamin D insufficiency and deficiency in US patients with chronic liver disease.
Miroliaee A, Nasiri-Toosi M, Khalilzadeh O, et al. Disturbances of parathyroid hormone-vitamin D axis in non-cholestatic chronic liver disease: a cross-sectional study. Hepatol Int. 2010;4(3):634–40.
Wills MR, Savory J. Vitamin D metabolism and chronic liver disease. Ann Clin Lab Sci. 1984;14(3):189–97.
Heaf JG. Hepatic osteodystrophy. Scand J Gastroenterol. 1985;20(9):1035–40.
American Gastroenterological Association medical position statement: osteoporosis in hepatic disorders. Gastroenterology. 2003; 125(3):937–40.
Cheng JB, Levine MA, Bell NH, et al. Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase. Proc Natl Acad Sci U S A. 2004;101(20):7711–5.
Michaud J, Naud J, Ouimet D, et al. Reduced hepatic synthesis of calcidiol in uremia. J Am Soc Nephrol. 2010;21(9):1488–97.
Hepner GW, Roginsky M, Moo HF. Abnormal vitamin D metabolism in patients with cirrhosis. Am J Dig Dis. 1976;21(7):527–32.
Wagonfeld JB, Nemchausky BA, Bolt M, et al. Comparison of vitamin D and 25-hydroxy-vitamin-D in the therapy of primary biliary cirrhosis. Lancet. 1976;2(7982):391–4.
Jung RT, Davie M, Hunter JO, et al. Abnormal vitamin D metabolism in cirrhosis. Gut. 1978;19(4):290–3.
Danielsson A, Lorentzon R, Larsson SE. Intestinal absorption and 25-hydroxylation of vitamin D in patients with primary biliary cirrhosis. Scand J Gastroenterol. 1982;17(3):349–55.
Chiu KC, Chu A, Go VL, et al. Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr. 2004;79(5):820–5.
Ford ES, Ajani UA, McGuire LC, et al. Concentrations of serum vitamin D and the metabolic syndrome among U.S. adults. Diabetes Care. 2005;28(5):1228–30.
Pittas AG, Lau J, Hu FB, et al. The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. J Clin Endocrinol Metab. 2007;92(6):2017–29.
Ybarra J, Sanchez-Hernandez J, Perez A. Hypovitaminosis D and morbid obesity. Nurs Clin North Am. 2007;42(1):19–27.
• Liangpunsakul S, Chalasani N: Serum Vitamin D Concentrations and Unexplained Elevation in ALT Among US Adults. Dig Dis Sci 2011, 56(7):2124–9. This study examined the relationship between vitamin D levels and unexplained elevation in ALT in the general population.
Temitope F, Chalasani N, Liangpunsakul S, et al.: The association of serum vitamin D concentrations and Non Alcoholic Fatty Liver Disease (NAFLD): the multi ethnic study of atherosclerosis. american association for the study of liver diseases, The Liver Meeting 2011 San Francisco, Abstract 1625. 2011.
Blum M, Dolnikowski G, Seyoum E, et al. Vitamin D(3) in fat tissue. Endocrine. 2008;33(1):90–4.
DiGiorgi M, Daud A, Inabnet WB, et al. Markers of bone and calcium metabolism following gastric bypass and laparoscopic adjustable gastric banding. Obes Surg. 2008;18(9):1144–8.
Bruno C, Fulford AD, Potts JR, et al. Serum markers of bone turnover are increased at six and 18 months after Roux-en-Y bariatric surgery: correlation with the reduction in leptin. J Clin Endocrinol Metab. 2010;95(1):159–66.
Pramyothin P, Biancuzzo RM, Lu Z, et al.: Vitamin D in adipose tissue and serum 25-hydroxyvitamin D after Roux-en-Y gastric bypass. Obesity (Silver Spring). 2011.
Takiishi T, Gysemans C, Bouillon R, et al. Vitamin D and diabetes. Endocrinol Metab Clin North Am. 2010;39(2):419–46. table of contents.
Vaidya A, Williams JS, Forman JP: The independent association between 25-hydroxyvitamin D and adiponectin and its relation with BMI in two large cohorts: the NHS and the HPFS. Obesity (Silver Spring). 2011.
Geier A. Shedding new light on vitamin D and fatty liver disease. J Hepatol. 2011;55(2):273–5.
• Targher G, Bertolini L, Scala L, et al.: Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2007, 17(7):517–24. Important study that suggests that low vitamin D levels are associated with fibrosis in patients with NAFLD.
Nakano T, Cheng YF, Lai CY, et al.: Impact of artificial sunlight therapy on the progress of non-alcoholic fatty liver disease in rats. J Hepatol 2010.
Beilfuss BA, Gieseler R, Zahn A: Intriguing relationship between vitamin D and liver fibrosis. 46th Annual Meeting of the European Association for the Study of the Liver Abstract #802April 17th 2010.
Selmi C, Mayo MJ, Bach N, et al. Primary biliary cirrhosis in monozygotic and dizygotic twins: genetics, epigenetics, and environment. Gastroenterology. 2004;127(2):485–92.
•• D’Aldebert E, Biyeyeme Bi Mve MJ, Mergey M, et al.: Bile salts control the antimicrobial peptide cathelicidin through nuclear receptors in the human biliary epithelium. Gastroenterology 2009, 136(4):1435–43. Intriguing study of potential role for vitamin D in the treatment of cholestatic liver disease.
Zanetti M. Cathelicidins, multifunctional peptides of the innate immunity. J Leukoc Biol. 2004;75(1):39–48.
Wang TT, Nestel FP, Bourdeau V, et al. Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J Immunol. 2004;173(5):2909–12.
Collier JD, Ninkovic M, Compston JE. Guidelines on the management of osteoporosis associated with chronic liver disease. Gut. 2002;50 Suppl 1:i1–9.
Lindor KD, Gershwin ME, Poupon R, et al. Primary biliary cirrhosis. Hepatology. 2009;50(1):291–308.
Chapman R, Fevery J, Kalloo A, et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology. 2010;51(2):660–78.
Cantorna MT, Hayes CE, DeLuca HF. 1,25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc Natl Acad Sci U S A. 1996;93(15):7861–4.
Cantorna MT, Zhu Y, Froicu M, et al. Vitamin D status, 1,25-dihydroxyvitamin D3, and the immune system. Am J Clin Nutr. 2004;80(6 Suppl):1717S–20S.
Hypponen E, Laara E, Reunanen A, et al. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet. 2001;358(9292):1500–3.
Bikle DD. Vitamin D and immune function: understanding common pathways. Curr Osteoporos Rep. 2009;7(2):58–63.
• Hu XD, Jiang SL, Liu CH, et al.: Preventive effects of 1,25-(OH)2VD3 against ConA-induced mouse hepatitis through promoting vitamin D receptor gene expression. Acta Pharmacol Sin 2010, 31(6):703–8. Intriguing study of vitamin D as an immune-modulating agent in autoimmune hepatitis.
van der Poorten D, George J. Disease-specific mechanisms of fibrosis: hepatitis C virus and nonalcoholic steatohepatitis. Clin Liver Dis. 2008;12(4):805–24. ix.
Shen L. Vitamin D controls T cell activation: implication for causal association between vitamin D deficiency and fibrosis in chronic hepatitis C. Hepatology. 2010;52(5):1864.
Lange CM, Bojunga J, Ramos-Lopez E, et al. Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy. J Hepatol. 2011;54(5):887–93.
Redaelli CA, Wagner M, Tien YH, et al. 1 alpha,25-Dihydroxycholecalciferol reduces rejection and improves survival in rat liver allografts. Hepatology. 2001;34(5):926–34.
•• Holick MF, Binkley NC, Bischoff-Ferrari HA, et al.: Evaluation, treatment, and prevention of vitamin d deficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2011, 96(7):1911–30. An excellent practice guideline for the management of vitamin D deficiency.
Acknowledgements
This work was supported in part by K24 DK069290A to N.C.
Disclosure
No potential conflicts of interest relevant to this article were reported.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lim, L.Y., Chalasani, N. Vitamin D Deficiency in Patients with Chronic Liver Disease and Cirrhosis. Curr Gastroenterol Rep 14, 67–73 (2012). https://doi.org/10.1007/s11894-011-0231-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11894-011-0231-7